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Introduction: Crohn's disease (CD) is an inflammatory bowel disease, marked by exacerbations and remis-
sions periods. Peripheral manifestations in CD may be present with the syndrome of skeletal muscle dys-
function (SMD), which is characterized by loss of muscle strength, fatigue complain, limited exercise capac-
ity and impaired quality of life of these patients. Objective: Evaluate muscle strength, physical capacity and 
quality of life of patients with CD and compare them with healthy controls. Methods: 18 patients CD and 12 
healthy controls matched for age and sex were involved. Peripheral muscle strength evaluated by handgrip 
strength of the dominant hand and respiratory muscle strength by measures of respiratory muscle strength 
(maximal inspiratory/expiratory pressure – MIP and MEP). Exercise capacity evaluated by Shuttle test (ST) 
and the quality of life by the Short-form 36 (SF-36) and by the Inflammatory Bowel Disease Questionnaire 
(IBDQ). Results: Patients with CD presented a lower respiratory muscle strength (MIP = -68.93 ± 26.61 
vs 29.63 ± -100 cmH2O, p = 0.0013 and MEP = 81.07 ± 30.26 vs 108 ± 25.30 cmH2O, p = 0.032) and a ten-
dency the lower peripheral muscle strength (31.72 ± 8.55 vs 39.00 ± 13.37 kgf, p = 0.09). In addition, CD 
patients presented worse physical capacity on the ST compared to the control group (513.7 ± 237m vs 983.0 ± 
263m, p < 0.05) and worse quality of life in 7 of 8 domains of the SF-36 and in all dimensions of the IBDQ. 
Conclusion: Patients with CD showed muscle functional impairment and poorer quality of life compared to 
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healthy control group. These findings suggest that the assessment and maybe interventions in the muscle 
function must be used in clinical practice.
Keywords: Crohn's Disease. Muscle Strength. Exercise. Quality of Life.
Resumo
Introdução: A doença de Crohn (DC) é uma doença inflamatória intestinal marcada por agudizações e remissões. 
Manifestações sistêmicas na DC podem estar associadas à síndrome da disfunção muscular esquelética (SDM), a 
qual é caracterizada por perda de força, queixa de fadiga, limitação ao exercício e prejuízo na qualidade de vida. 
Objetivo: Avaliar a força muscular, a capacidade de exercício e a qualidade de vida de pacientes com DC e com-
pará-los com controles saudáveis. Métodos: Foram envolvidos 18 pacientes com DC e 12 controles saudáveis pare-
ados por idade e sexo. A força muscular periférica foi avaliada pela força de preensão palmar da mão dominante; e 
a força muscular respiratória pelas medidas de pressões respiratórias máximas (pressão inspiratória/expiratória 
máxima – PIM e PEM). A capacidade ao exercício foi avaliada por meio do teste de Shuttle (TS) e a qualidade de 
vida pelo relacionada à saúde pelo Short Form-36 e pelo The Inflammatory Bowel Disease Questionnaire (IBDQ). 
Resultados: A força muscular respiratória mostrou-se reduzida nos pacientes com DC comparado ao grupo con-
trole (PIM = -68,93 ± 26,61 vs -100 ± 29,63 cmH2O, p = 0,0013 e PEM = 81,07 ± 30,26 vs 108 ± 25,30 cmH2O, 
p = 0,032) e, com tendência a menor força muscular periférica no grupo de pacientes (31,72 ± 8,55 vs 39,00 ± 
13,37 kgf, p = 0,09). Pacientes com DC apresentaram ainda pior capacidade de exercício no TS (513,7 ± 237m vs 
983,0 ± 263m, p < 0,05) e pior qualidade de vida comparados aos controles. Conclusão: Pacientes com DC mostr-
aram prejuízo funcional muscular e pior qualidade de vida. Estes achados sugerem que a avaliação e possível 
intervenção da função muscular deve ser adotada na prática clínica.
Palavras-chave: Doença de Crohn. Força Muscular. Exercício. Qualidade de Vida.   
Introduction
Crohn's disease (CD) is an inflammatory bowel 
disease of unknown origin characterized by the focal 
involvement, transmural and asymmetric of any part 
of the digestive tract, from mouth to anus (1). It is not 
clinically or surgically curable and its natural history 
is marked by acute exacerbations and remissions. The 
prevalence and incidence in developed countries are 
around 5:100.000 and 50:100.000 respectively. An 
estimative of the prevalence in the city of São Paulo 
found out 14.8 cases per 100,000 inhabitants (2). The 
CD starts most often in the second and third decades 
of life, but it can affect any age group.
   It is believed that intestinal damage in CD oc-
curs as a result of an exaggerated response of the 
immune system against its own intestinal flora. It has 
cyclical course alternating between active and remis-
sion phase, with frequent intestinal manifestations 
of abdominal pain and diarrhea, fistula formation 
and intestinal obstructive symptoms (3). Besides 
the manifestations of the digestive system, the CD 
can show extra intestinal manifestations, the most 
frequent being ophthalmic (such as uveitis) of the 
skin (such as erythema nodosum), rheumatic, and 
often even osteoporosis and arthralgia, as well as 
malnutrition, fatigue and state of pre cachexia, which 
increases the potential for complications (4).
   Faced with CD's systemic manifestations, it is 
suspected that the presence of skeletal muscle dys-
function syndrome (SMD). This syndrome is charac-
terized by atrophy (sarcopenia or pre-cachexia), loss 
of muscle strength and resistance, which limit the 
physical capacity. Although its etiology is not yet fully 
understood, it is likely that the SMD may be multifac-
torial, involving aspects such as nutritional depletion, 
systemic inflammation, chronic or repeated use of 
glucocorticoids, physical deconditioning related to 
physical inactivity, which may explain the significant 
symptoms of fatigue in patients with CD (5, 6).
   Considering that in patients with CD in the active 
form the inflammatory peak and the use of glucocor-
ticoids are accentuated, can be hypothesized that pe-
ripheral consequences can be even more significant 
Fisioter Mov. 2017 Apr/June;30(2):337-45
Muscle function and quality of life in the Crohn’s disease
339
on Human of the Federal University of Juiz de Fora, 
under the protocol number 95.125/2012. 
Procedures
Peripheral muscle strength - manual 
dynamometry:
The peripheral muscle strength was obtained 
from the maximal voluntary contraction manual 
prehension or simply manual dynamometry (MD) 
(12). For this measure was used Jamar® hydrau-
lic dynamometer.
The guidelines and position used were those 
recommended by the American Society of Hand 
Therapists (13). Grip strength of the dominant hand 
was evaluated and taken three measures with an in-
terval of three minutes between each contraction, 
with verbal encouragement during the test. The 
considered contraction force was that in which the 
patient was able to maintain the maximum reached 
value for at least three seconds. 
Respiratory muscle strength:
The respiratory muscle strength evaluation was 
taken by the manovacuometer with range of ± 300 
cmH2O (Gerar ®, São Paulo - Brazil). The measures 
of maximal respiratory pressures MIP and MEP 
were performed in accordance with previous deter-
minations (14), while the volunteers were seated, 
using a nose clip and mouthpiece between his lips. 
The measurement was considered completed when 
the individual performed five acceptable measures, 
and among these, a minimum of two reproducible 
ones. The last value found can not be higher than 
the other, when it occurred, the maneuver was 
repeated until the last value was shorter than or 
equal to the last, considering the learning effect. 
The acceptable maneuvers were those with no air 
leaks between the lips, with a maximum pressure 
support of at least one second, and reproducible, 
in other words, with a variation shorter than or 
equal to 10% of the highest value. All strength rat-
ings of the respiratory muscles were made by the 
same person, properly trained to do so. The values 
obtained were compared with the reference values 
determined by Neder et al. (15).
in this disease's phase, and that coincide with the 
weight loss and fatigue complaints. Based on these 
assertions, and given the current limited literature 
(7 - 10), particularly as regards the assessment of 
the muscle function, exercise capacity and life qual-
ity in patients with CD, it is crucial to study deeper 
the behavior of these variables in individuals with 
CD. Thus, this study aimed to evaluate the peripheral 
muscle strength (grip strength) and central (respira-
tory muscle strength), the phisical capacity and qual-
ity of life in patients with CD in the active phase of the 
disease, as well as compare them to healthy controls.
Methods 
Participants
This is a cross-sectional study (conducted from 
February 2013 to April 2014) whose sample con-
sisted of 18 patients who would start the biological 
drug therapy with anti-TNFα and therefore classified 
as the active phase of the disease. These were owned 
by the Gastroenterology Clinic of the Universitary's 
Hospital Health Attention Center of the Juiz de Fora 
Federal University (UH / HAC JFFU) with clinical di-
agnostics, endoscopic and histological confirmed and 
12 healthy control subjects matched by age and sex. 
The study enrolled patients with active CD, classified 
as moderate to severe by Harvey-Bradshaw Index 
(11) > 6, corticodependent and / or refractory to 
immunosuppressants, with complicated fistula and 
older than 18 and younger than 65 years.
Healthy volunteers were matched by age and sex 
considering two years more or less in relation to the 
group with CD, according to the following criteria: 
be apparently healthy; do not report chronic disease 
(excluding systemic controlled hypertension) and be 
able to perform all tests. Were adopted as exclusion 
criteria for all participants: Pregnant women, with 
a history of bariatric surgery, extreme diet practi-
tioners (eg.: macrobiotic or vegetarian), with celiac 
disease, with extensive resection of the small intes-
tine, associated comorbidities, major musculoskeletal 
limitations which could influence the tests and cogni-
tive losses that could prevent the understanding of 
the procedures.
Every participant signed a consent form, and all 
procedures were approved by the Ethics Committee 
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Additionally, in the group of patients with CD was 
used the Inflammatory Bowel Disease Questionnaire 
(IBDQ), originally created by Gyatt et al (20). This 
questionnaire is specific for intestinal inflammatory 
diseases (IID) such as CD and ulcerative colitis, has 
been translated, validated, and tested the psycho-
metric properties for Portuguese (21). It consists of 
32 questions that evaluate different aspects of life 
quality for the previous 15 days, and are grouped 
into four areas: intestinal symptoms and systemic, 
social function and emotional. Originally, the score 
is obtained according to a Likert scale of 1 to 7, with 
1 corresponding to the worst health status and 7 to 
the best health. The sum of points obtained in each 
domain takes place, and the total sum of each domain 
will result in the pacient's overall score. The total 
score can range from 32 to 224. Based on clinical 
studies using IBDQ (22 - 24), we follow the rating 
for the quality of life in this study: ≥ 200 = excellent; 
151-199 = good; 101-150 = regular; ≤ 100 = bad.
Data analysis:
The data were tabulated and analyzed using 
SPSS 17.0 for Windows (SPSS Inc, Chicago, USA). 
Data were expressed average ± standard devia-
tion or median (and minimum-maximum) when 
appropriate. Normality was tested by the Shapiro-
Wilk test. For comparison between groups was per-
formed Student t test unpaired or Mann-Whitney, 
as the data were parametric or not, respectively. 
The probability for type I error was assumed to be 
5% in all tests (p ≤ 0.05).
Results 
Initially, 29 patients with CD were recruited, 11 
were excluded according to the criteria: morbid obe-
sity (1), comorbidities (4), depression (1), extensive 
resection of the bowel (1), refusal to participate in 
the study (4). However, the final sample consisted of 
18 patients with CD and 12 healthy controls.
   All patients with CD were in the active stage of 
the disease characterized by Harvey-Bradshaw index 
of 6.7 and by the repetitive or chronic use of gluco-
corticoids in the last 6 months, besides the use of 
azathioprine since the disease's diagnosis.
Physical capacity:
The maximum physical capacity was assessed by 
the incremental Shuttle test (ST) (16). The ST consists 
of walking on flat ground, running repetitively a dis-
tance of 10 meters around a marking of two cones. 
The only acoustic sound indicates the time in which 
the individual must go through the predetermined 
distance, reaching the cone and change direction, re-
turning to the other cone, while the triple acoustic 
signal indicates the need to increase the speed to 
cover the distance between the cones.
At every minute, the time between the acoustic 
signals reduces so that the individual should increase 
the walking speed to reach the cone at the right time 
(increased every minute of 0,17m/s). The end of 
test is determined when the individual fails, for the 
second (17) to complete the distance between the 
cores within the allowed time, that is, when is more 
than 0.5m cone when the beep sound or when shows 
symptoms of fatigue of the lower limbs or intolerable 
dyspnea (16). It is therefore an incremental test with 
stages up to 12 levels of speed that produces a similar 
physiological load test similar to an incremental cycle 
ergometer test (18).
The values obtained were compared with the 
reference values determined by Probst et al. (17), 
given by the following formula: Predicted distance  = 
1449.701 - (11.735 x age) + (241.897 x gender) - 
(5,686 x BMI), where: male = 1, female = 0. The out-
come measures of this test were the total distance 
covered, the stage level achieved in the test and the 
percentage of the predicted distance.
Quality of life:
The health-related quality of life in general terms 
was evaluated in both groups of patients and con-
trols through the health-related quality of life - Short 
Form 36 (SF36). The SF-36 is a generic questionnaire, 
validated in Portuguese (19) and distributed in eight 
domains: limitations in physical activity due to health 
problems; limitations for physical health problems; 
Vitality on energy and fatigue; pain in the body; 
general mental health; limitations due to emotional 
problems; perception of general health; and social 
aspect. The score for each of the domains of the SF-36 
questionnaire ranges from zero (worst health status) 
to one hundred (better health status).
Fisioter Mov. 2017 Apr/June;30(2):337-45
Muscle function and quality of life in the Crohn’s disease
341
level - showed differences between groups, and the 
CD group traveled less distance if compared to the 
control group.
The Table 2  have shown the scores obtained in the 
8 domains of the life quality questionnaire related to 
the health SF-36. Of the 8 domains, only the domain 
"Limitations due to emotional problems" showed no 
difference. In the other, the CD group had worse life 
quality self-report compared to the control group.
In relation to the domains of the life quality spe-
cific questionnaire for inflammatory bowel disease, 
the IBDQ, this was applied only in patients with CD. 
The scores in medians and minimum and maximum 
values of the domains were systemic aspects 44 (28 - 
70); intestinal aspects 19 (8 - 34); social aspects 27 
(7 - 35); emotional aspects 14 (0 - 21); and complete 
94 (58-154). All patients had values corresponding 
to the low quality of life (total score <170).
Table 1 shows the demographic characteristics of 
muscle strength and physical capability of the sample. 
It was allowed to pair a control with the same age and 
sex for each two patients, which explains the differ-
ence in the sample size of each group. It is observed 
that there was no difference between the average 
age of both groups. In relation to BMI was difference, 
wherein the average BMI of the group with CD lower 
than the average healthy controls.
In Table 1 are also shown the muscle strength and 
physical function data in both groups. Although it 
can be observed a tendency of handgrip to be lower 
in patients with CD, this was not significantly dif-
ferent (p = 0.09). Furthermore, shown differences 
between the values of both MIP as MEP between the 
patient and control groups, showing lower values for 
the CD group. As for the analysis of physical capacity 
by TS - distance, predicted percentage and reached 
Table1 - Demographic characteristics of muscle strength and physical capability of the sample 
CD Group Control Group Value of p
Demographic data
Age (in years) 38.56±13.69 37.30±13.22 0.834
BMI (Kg/m²) 22.45± 2.97 25.52±3.19 0.018*
Gender 11f/7m 7f/5m --
HBI 6.7 --
Respiratory Muscle Strength
MIP (cmH2O) -68.93 ± 26.61 -100 ±29.63 0.013*
Maximum Predicted IP% 64.26 ±21.70 94.10±28.16 0.011*
MEP (cmH2O) 81.07±30.26 108 ±25.30 0.032*
Maximum Predicted EP% 72.28 ±27 97.56 ± 24.98 0.046*
Peripheral Muscle Strength
Handgrip Strength (Kgf) 31.72 ± 8.55 39.00 ± 13.37 0.09
Physical Capacity
Covered Distance (m) 513.7 ± 237 983.0 ± 263 0.001*
Predicted Distance (%) 55.09 ± 22.90 102.24 ± 19.62 0.001*
Shuttle Level 8.11 ± 2.16 11.8 ± 1.93 0.001*
Table 2 - Characterization of health-related quality of life by SF-36 
SF-36 Domains CD Group Control Group Value of p
Fuctioning Capacity 70 (0-100) 100 (75-100) 0.001*
Physical Aspects Limitations 50 (0-100) 100 (50-100) 0.004*
Pain 51 (10-100) 92 (51-100) 0.006*
General Health Status 52 (42-82) 88.5 (62-100) 0.000*
Vitality 55 (10-100) 67.5 (55-95) 0.017*
Social Aspects 50 (12.5-100) 93.75 (25-100) 0.049*
Emotion Aspects Limitations 66 (0-100) 100 (0-100) 0.10
Mental Health 60 (20-96) 84 (48-92) 0.023*
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Discussion 
The results of this study show that patients with CD 
in the active phase of the disease show: reduced mus-
cle strength, reduced physical capacity and loss on life 
quality when compared to healthy controls. This study 
aimed to evaluate muscle function, physical capacity 
and life quality in patients with CD in the active phase 
of the disease, once that at this stage the inflammatory 
peak and malabsorption of nutrients lead to anemia, 
malnutrition, fatigue and longer home confinement 
time due to increased bowel frequency (4).
Although the drug treatment done with cortico-
steroids assists the inflammation control in the ac-
tive phase of the disease, it is known that chronic or 
repeated use of this leads to the lysis of myofibrils 
which may compromise the physical function and life 
quality of these patients (25 - 26). This study showed 
a reduction in respiratory muscle strength and a ten-
dency to decrease in peripheral muscle strength in 
patients with CD, which can be explained by the range 
of factors that involves the inflammatory, nutritional 
and therapeutic aspects of the disease.
Muscle strength and exercise capacity are in-
dicative parameters of muscle function. The muscle 
weakness and fatigability results in loss of perfor-
mance and consequently worst quality of life. Muscle 
strength is derived from the motor units composed 
of fibers of slow and fast twitch, i.e. type I fibers, IIa 
and IIb, respectively. This property, strength, depends 
on some intrinsic characteristics, such as: (i) the 
number of fibers innervated by a motor neuron; (ii) 
cross-sectional area of muscle fibers within the unit; 
(iii) percentage of specific fibers of muscle strength; 
(iv) number of motor units recruited; (v) contrac-
tion velocity and (vi) muscle tensio-length relation. 
Changing any of these properties results in muscular 
weakness, which reduces exercise capacity and in-
creases the intensity of the symptoms of fatigue (27).
Several studies determine cofactors that lead to 
loss of muscle strength in chronic inflammatory dis-
eases (27 - 29). The pathological mechanisms that in-
volves systemic inflammation, inadequate nutrition, 
hormonal dysfunction or adverse effects of cortico-
steroid drugs can lead to atrophy, chronic inactivity 
and fatigue, further corroborating the disuse atrophy, 
which are the probable etiology of muscle dysfunc-
tion in patients with CD (26 - 29).
Other studies in patients with other chronic, 
also, inflammatory diseases showed associations 
peripheral, respiratory and muscle strength reduc-
tions with the severity of the disease, with postop-
erative complications, worsening of life quality, sar-
copenia and with an inflammatory markers increase 
(30, 31). Spruit et al. (29) observed a negative re-
lationship between the peripheral muscle strength 
reduction and the elevated systemic inflammation 
in acute exacerbation of COPD. This analogy can be 
made between patients with exacerbated COPD and 
CD patients in the active stage of the disease, when 
the inflammatory stress is enhanced, the use of hor-
monal anti-inflammatory therapy and greater physi-
cal inactivity occurs.
Although the inflammatory profile of patients in 
this study was not objectively assessed, we assume 
that according to the HBI, which indicates the stage 
of the disease in which the patient is (active or re-
mission), all patients involved in this study were in 
the active phase of the disease determined by HBI 
6.7. At this stage of the disease, the inflammatory 
stress and the exacerbation of intestinal and extra 
intestinal symptoms are more pronounced requiring 
corticosteroid therapy (4).
It is well known that in chronic inflammatory dis-
eases the continued use of corticosteroids causes the 
involvement of the proximal muscles occurs prior 
to the distal (26, 32). In this logic, one could suggest 
that the manual dynamometry can neglect peripheral 
muscle weakness by assessing a limited muscle group 
(upper limbs), especially if the disorder involves pri-
marily proximal muscles or yet locomotor muscles. 
In this context, it can be assumed that this method 
has low sensitivity in the evaluation of muscle func-
tional deficit, suggesting that specific segmental re-
views of proximal muscles and lower limbs should 
be considered.
On the other hand, the respiratory muscle strength 
showed differences between the groups, and both the 
average values of MIP as MEP were lower in the CD 
group, which seems to be more consonant with the 
proximal muscles. The reduction in expiratory muscle 
strength (MEP) brings indicative that patients have 
worse performed of abdominal muscles, muscles 
that is enabled in the forced expiration, in cough and 
defecation (33). The reduction in inspiratory muscle 
strength suggests that the diaphragm and the acces-
sory inspiration muscles (sternocleidomastoid, sca-
lene, intercostal) also showed worse performance 
when compared to the control group. However, the 
reduction in respiratory muscle strength observed in 
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muscle dysfunction, with a consequent loss in physi-
cal activity and social activities (8). Complementing 
the generic life quality questionnaire (SF-36), the spe-
cific questionnaire quality of life for IBD, the IBDQ, 
has also been applied in patients with CD, and this 
pointed to a poor life quality of those with a score of 
94 ( <100 points).
Different studies show that life quality is com-
promised in patients with IBD (8, 35, 36). Bernklev 
et al. (37) compared the life quality auto account of 
514 IBD patients (348 with ulcerative colitis and 166 
with CD) and 2323 healthy Norwegians. The results 
showed that in patients with UC the scores of 6 of 
the 8 domains of the SF-36 were below the healthy 
population and in patients with CD were below in 7 
of the 8 domains.
Despite the absence of direct measurements, such 
as tissue biopsy, to confirm enzymatic, biochemical 
and metabolic alterations of muscle fibers, the results 
presented here, supported in the literature subsidies, 
allow us to guess that CD patients have muscle dys-
function with repercussions in physical capacity and 
life quality of thereof. This finding carries important 
clinical implications, because from the assumption 
physical rehabilitation strategies should be consid-
ered in order to improve physical function and life 
quality of this population.
The present study has limitations such as the 
small sample size, the involvement of only patients 
in the active phase of the disease and its design of 
the cross-sectional study. Although the sample was 
modest, it is a disease of low prevalence in the popu-
lation, but nonetheless was possible to detect signifi-
cant differences in most variables. In this hand, it is 
crucial to continue this line of research and perform 
another study phase with longitudinal templates, to 
investigate the impact of therapeutic interventions 
in CD patients with muscular dysfunction.
Conclusion
From the observed results we can conclude that 
CD patients have impaired muscle strength, in the 
exercise capacity and life quality compared to healthy 
subjects. While it is necessary more studies investi-
gating the muscle function in patients with CD, the 
data from this study suggest that the assessment of 
muscle function should be adopted in clinical practice.
patients with CD does not have to date clinical impor-
tance, because although with lower values than con-
trols, they do not suggest muscle fatigue, mechanical 
ventilatory insufficiency, or perception of dyspnea 
that justify specific intervention of this muscle group. 
After literature review, only one case report of pacient 
with CD and peripheral and respiratory muscle weak-
ness was found, although in this case the patient had 
polymyositis associated (34). However, our findings 
may help to elucidate how the muscles can be affected 
heterogeneously in this population.
Although the muscle function of the locomotor 
muscles have not been used, it is known that the lower 
limbs muscle strength reduction is an event that leads 
to intolerance to exercise, which is intensified in the 
active disease phasewith physical deconditioning. In 
the comparison between groups, the CD group trav-
eled less distance in the ST than the control group, 
which corresponded to about 50% of the predicted 
distance. Otto et al analyzed the physical capacity of 
534 adults with various gastrointestinal diseases, 
including IBD, by maximum cardiopulmonary effort 
test in the preoperative evaluation and concluded 
that patients with CD had lower anaerobic threshold 
if compared to cancer patients and other diseases 
colorectal (7). These findings corroborate the results 
of the reduced physical capacity in patients with CD 
found in this study. There is evidence that patients 
with CD have a lower proportion of muscle fibers 
type I, fibers that determine exercise tolerance (35). 
The physical capacity reduction can be attributed to 
high levels of pro-inflammatory cytokines, by the high 
frequency of daily bowel movements, by the nutri-
tional malabsorption, by inactivity and by the use of 
systemic corticosteroids (7).
Similarly, Ploeger et al. (8) found that pediatric 
patients with inflammatory bowel disease using 
corticosteroids had aerobic capacity reduced when 
compared to those not taking the drug, despite the 
lean body mass is not decreased, showing the in-
fluence of drug therapy in the exercise capacity of 
these patients.
In the present study it was even observed that 
in patients with CD, the life quality related to health 
was worse in 7 of the 8 areas that compose it. The de-
crease in quality of life in these patients is easily un-
derstood by the frequent manifestation of intestinal 
symptoms such as diarrhea and abdominal and extra 
bowel pain, as weight loss, anemia, fever, arthralgia, 
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